Current Report Filing (8-k)
September 10 2019 - 8:08AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): September 10, 2019
DELMAR
PHARMACEUTICALS, INC.
|
(Exact
Name of Registrant as Specified in its Charter)
|
|
Nevada
|
|
001-37823
|
|
99-0360497
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
12707
High Bluff Dr., Suite 200
San
Diego, CA 92130
(Address
of Principal Executive Offices) (Zip Code)
Registrant’s
telephone number, including area code: (604) 629-5989
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13-e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
DMPI
|
|
The
Nasdaq Capital Market
|
Item
2.02 Results of Operations and Financial Condition.
DelMar
Pharmaceuticals, Inc. (the “Company”) issued a press release on September 10, 2019, disclosing financial information
and operating metrics for its fiscal year ended June 30, 2019, and discussing its business outlook. A copy of the Company’s
press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item
7.01 Regulation FD Disclosure.
See
“Item 2.02 Results of Operation and Financial Condition” above.
The
information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1,
is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and
shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended or the Securities
Exchange Act of 1934, as amended, except as shall be expressly set forth by a specific reference in such filing.
Item
9.01 Financial Statements and Exhibits.
(d)
The following exhibit is furnished with this report:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
DELMAR
PHARMACEUTICALS, INC.
|
|
|
Date:
September 10, 2019
|
By:
|
/s/
Scott Praill
|
|
|
Scott
Praill
|
|
|
Chief
Financial Officer
|
3
DelMar Pharmaceuticals (NASDAQ:DMPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
DelMar Pharmaceuticals (NASDAQ:DMPI)
Historical Stock Chart
From Apr 2023 to Apr 2024